ESTRO Multidisciplinary Management of Breast Cancer 2017

NTCP models using individual patient data of 2 large trials

• Development of model using pooled data of: boost no boost trial & Cambridge IMRT trial • Validated using the START-pilot trial

• EQD2 for 50% risk on moderate/severe fibrosis: about 80 Gy

Mukesh et al, 2013